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Abstract
Background: Intermittent preventive treatment of malaria in infants (IPTi) consists of the administration of a
treatment dose of sulphadoxine-pyrimethamine (SP) at the time of routine vaccinations. The use of routine Health
Management and Information Services (HMIS) data to investigate the effect of IPTi on malaria, anaemia, and all-
cause attendance in children aged 2-11 months presenting to 11 health centres in southern Tanzania is described.
Methods: Clinical diagnosis of malaria was confirmed with a positive blood slide reading from a quality assurance
laboratory. Anaemia was defined using two thresholds (mild [Hb < 11 g/dL], severe [Hb < 8 g/dL]). Incidence rates
between IPTi and non-implementing health centres were calculated using Poisson regression, and all statistical
testing was based on the t test due to the clustered nature of the data.
Results: Seventy two per cent of infants presenting in intervention areas received at least one dose of IPTi- 22%
received all three. During March 2006 - April 2007, the incidence of all cause attendance was two attendances per
person, per year (pppy), including 0.2 episodes pppy of malaria, 0.7 episodes of mild and 0.13 episodes of severe
anaemia. Point estimates for the effect of IPTi on malaria varied between 18% and 52%, depending on the scope
of the analysis, although adjustment for clustering rendered these not statistically significant.
Conclusions: The point estimate of the effect of IPTi on malaria is consistent with that from a large pooled
analysis of randomized control trials. As such, it is plausible that the difference seen in health centre data is due to
IPTi, even thought the effect did not reach statistical significance. Findings draw attention to the challenges of
robust inference of effects of interventions based on routine health centre data. Analysis of routine health
information can reassure that interventions are being made available and having desired effects, but unanticipated
effects should trigger data collection from representative samples of the target population.
Background
The contribution of Plasmodium falciparum-caused
malaria to mortality and morbidity of African infants and
young children remains substantial [1]. Malaria control
strategies throughout the African continent have seen
considerable increases in financial and human resources
investment from governments, non-governmental agen-
cies, and funders alike [1]. The monitoring and evalua-
tion of malaria control programmes is essential, and
recently more emphasis has been placed on both by the
WHO’s Global Malaria Programme and by the Roll Back
Malaria (RBM) partnership. RBM’s Monitoring and Eva-
luation Reference Group (MERG) recommends a number
of data collection methods to monitor and evaluate
malaria control strategies, and highlights as currently
under-exploited, the use of routine health management
and information system, particularly from randomly-
selected malaria sentinel sites [2,3].
Intermittent preventive treatment of malaria in infants
(IPTi) consists of the administration of a treatment dose
of sulphadoxine-pyrimethamine (SP) at the time of rou-
tine vaccinations in the first year of life [4]. In a pooled
analysis of six randomized controlled trials (RCTs) of
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IPTi using SP, the incidence of clinical malaria in the
first year of life was reduced by 30% [5], and IPTi was
considered a safe and effective anti-malarial strategy,
likely to form a useful component of malaria control
programmes in relevant settings [6]. In addition to
RCTs [5,7-12], studies addressing questions of cost
[13,14], safety, drug resistance [15], acceptability [16,17],
and the implementation of IPTi through the Expanded
Programme on Immunization (EPI) [18] have also been
carried out, under the umbrella of the IPTi consortium
[19]. The community effectiveness of IPTi and its
impact on infant health has been investigated in Tanza-
nia through a cluster-randomized controlled trial includ-
ing representative pre and post-intervention household
surveys [20,21].
In this paper, data from a consolidated HMIS in 11
sentinel health centres in rural southern Tanzania are
used to report (i) the uptake of IPTi and coverage of
corresponding EPI vaccines, (ii) the incidence of malaria,
anaemia, and all-cause attendance at the health centre,
and (iii) the effectiveness of IPTi on the incidence of
these outcomes in health centre attendees aged 2-11
months.
Methods
Study area and the IPTi strategy
The area has been previously described, but briefly
malaria is endemic, with transmission occurring
throughout the year, and is the most common primary
cause of health centre or hospital admission among
those aged under five years [20,22]. The first-line anti-
malarial drug in this area was SP, until December 2006,
when it changed to artemether-lumefantrine. During the
study period a number of malaria control interventions
were implemented. Nationwide, from May 2006, the
Tanzania National Voucher Scheme was in effect, deli-
vering bed nets bundled with insecticide re-treatment
kits to pregnant women through vouchers available at
antenatal care clinics [23]. Health centres nationwide
also distributed free insecticide re-treatment kits to
infants when they attended government clinics for
measles vaccination. Furthermore, in Lindi region
(Figure 1) during August 2005, bed nets bundled with
insecticide were distributed to children aged less than
five years during an integrated mass measles vaccination,
helminth treatment, and vitamin A supplementation
campaign [24].
This study, termed the IPTi Morbidity Monitoring
study, took place in the context of a large cluster rando-
mized trial that was designed to determine the commu-
nity effectiveness of IPTi with SP on malaria and
anaemia. IPTi using SP was introduced to 12 of 24 ran-
domly selected divisions, located within five districts,
and two regions (Lindi and Mtwara) of rural southern
Tanzania (Figure 1) [22]. IPTi effectiveness was esti-
mated through representative household surveys that
took place in all 24 participating divisions at baseline in
2004 (n = 21,600), and post IPTi in July/August 2006
(n = 5,760) [20]. IPTi, in the form of a single dose of
SP, was delivered in intervention divisions through exist-
ing government health centres when children presented
for their routine EPI vaccine doses of DPT2, DPT3, and
measles (given at two, three, and nine months of age,
respectively). Children presenting at government health
centres in comparison divisions received their routine
EPI vaccine, but no IPTi.
The IPTi Morbidity Monitoring study, data collection and
outcome definition
The Morbidity Monitoring study aimed to monitor the
delivery of IPTi with SP through routine contacts with the
health service, and to enable evaluation of the effectiveness
of IPTi using routine health centre data. All 11 health cen-
tres with functional microscopes in the study area were
included. These were located in 11 of the 24 divisions
included in the IPTi trial, six in intervention, and five in
comparison areas (Figure 1, Table 1). On the basis of rou-
tine data available for 2004, intervention and comparison
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Figure 1 Map of the study area within Tanzania (a), and the 11
divisions included in the Morbidity Monitoring study (b). Note:
In map (b) IPTi intervention divisions are shown with diagonal
shading, comparison divisions with dotted shading, and Morbidity
Monitoring sentinel health centres by orange triangles.
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areas for this study were comparable. The total catchment
population was 68,938 in comparison areas, compared to
69,042 in IPTi-intervention areas. Analysis of routine
health centre data suggested that overall malaria incidence
was similar in intervention (1.05 episodes per child per
year) and comparison areas (1.10 episodes per child per
year), and measles vaccination coverage was also similar
(1,647 doses in comparison versus 1,594 doses in interven-
tion areas). Implementation of the Morbidity Monitoring
was staggered, beginning in 2005, but a period of maximal
functionality was defined as the 12 months between April
2006 and March 2007, and results in this paper refer to
this period.
Routine HMIS data, including demographic informa-
tion, Outpatient department attendance (OPD) and
vaccination records were captured electronically by
study-trained local school leavers, using Personal Digital
Assistants (PDAs) (Palm m130) [25], and records were
linked using an identification code. Each PDA operator
was working full-time in one of the 11 health centres.
They were supported by the study’s data entry clerk
who visited each health centre monthly.
Table 1 Distribution of children by health centre, characteristics of the Morbidity Monitoring study population, and
uptake of EPI and IPTi doses
Intervention Comparison p value *
Number children per health centre [n, (%)] n = 5035 n = 4845
A 486 (4.9)
B 869 (8.9)
C 862 (8.7)
D 999 (10.1)
E 951 (9.6)
F 868 (8.8)
G 840 (8.5)
H 519 (5.2)
I 1198 (12.1)
J 1610 (16.3)
K 678 (6.9)
Demographic characteristics
Sex [n/N, (%)]
Male 2567/5035 (51) 2514/4845 (52) 0.525
Birth order [n/N, (%)]
Singleton 4912/5035(98) 4685/4845 (97) 0.533
Median age at entry into analysis [months, (IQR)] 4 m 3 d (2 m-7 m 24 d) 4 m 12 d (2 m-7 m 27 d) 0.742
Health centre attendance
≥1 health centre attendance [n/N, (%)] 2160/5035 (43) 2067/4845 (43) 0.799
Median number of attendances (IQR) 2 (1-3) 2 (1-3) 0.892
EPI vaccine uptake [n/N, (%)]
DPT dose 2 3618/5035(72) 3181/4845 (66) 0.204
DPT dose 3 2889/4794 (60) 2296/4662 (49) 0.019
Measles vaccine 1609/3208 (50) 1009/3065 (33) 0.003
Median age at EPI vaccinations [months, (IQR)]
DPT dose 2 2 m 18 d(2 m 6 d-3 m 9 d) 2 m 24 d (2 m 9 d-3 m 21 d) 0.435
DPT dose 3 4 m 0 d(3 m 9 d-5 m 0 d) 4 m 3 d (3 m 12 d-5 m 9 d) 0.585
Measles vaccination 9 m 18 d (9 m 6 d-10 m 15 d) 9 m 15 d (9 m 3 d-10 m6 d) 0.099
IPTi uptake [n/N, (%)]
IPTi (at least one dose) 3627/5035 (72)
IPTi (all three doses) 1133/5035 (22)
Median age at IPTi doses [months, (IQR)]
IPTi dose 1 2 m 15 d (2 m 3 d-3 m 6 d)
IPTi dose 2 4 m 0 d (3 m 9 d-5 m 0 d)
IPTi dose 3 9 m 18 d (9 m 3 d-10 m 12 d)
* Using unpaired t test p value and approximate 95% CI that adjust for clustering by health centre.
EPI = expanded programme on immunization, IQR = inter-quartile range, m = months, d = days.
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In addition to routine HMIS data, blood slide readings
for malaria parasites and haemoglobin data were also col-
lected. Malaria parasite blood slides were prepared using
Giemsa staining, and parasite counts per 200 white blood
cells (WBCs) were calculated [26,27], while haemoglobin
was measured using the Haemoglobin Colour Scale [28].
Following reading at the health centre, malaria parasite
blood slides were stored and read twice in the Morbidity
Monitoring study’s quality assurance (QA) laboratory by
two independent slide readers [26,29]. Malaria in this
study was defined as a health centre attendance which
resulted in both a recorded malaria diagnosis by the
health centre clinician, and a positive blood slide reading
(≥1 parasite/200 WBCs) from the QA laboratory. Health
centre blood slide results were not used to define malaria,
as these had an average sensitivity of 89.6% and specifi-
city of 77.3%, using the quality assurance laboratory as
the gold standard, and variability between health centres
was seen. Anaemia was defined using two thresholds;
mild anaemia was a haemoglobin (Hb) concentration
below 11 g/dL, and severe anaemia used a threshold of
Hb < 8 g/dL.
Statistical methods
Data from PDAs were exported using Pendragon Forms
software to Microsoft Access for data management, and
subsequently to Stata 10.0 for statistical analysis (Stata
Corp., College Station, TX, USA). Analysis was done
according to a pre-agreed analytical plan, incorporating
both ‘intention to treat’ and ‘per protocol’ analyses. In
‘intention to treat’ analyses, all children attending a sen-
tinel health centre located in divisions randomized to
receive IPTi were compared with those attending senti-
nel health centres located in IPTi comparison divisions.
For the ‘per protocol’ analyses, children attending health
centres in intervention areas who had received IPTi
were compared with those attending health centres in
comparison areas who had received the corresponding
EPI vaccines.
Time at risk for malaria, anaemia, and OPD incidence
rate calculations began at the latest of the following:
date of registration in the consolidated HMIS, date of
becoming two months old, or start date of the study (1st
April 2006), and ended at the earliest of either becoming
12 months of age, or the end date of the study (31st
March 2007). In order to avoid double-counting the
same malaria episode as two separate episodes, 28 days
follow up was removed after each malaria diagnosis in
analyses of multiple episodes of malaria. Incidence rates
were calculated using Poisson regression, and incidence
rates of multiple episodes of malaria or all-cause health
centre attendance were adjusted for within-child cluster-
ing using random effects Poisson regression modelling.
The protective efficacy of IPTi was defined as (1-RR) × 100,
where RR is the rate ratio. All statistical testing was based
on the t test, using a summary measure of the data from
each health centre, to take into consideration the clus-
tered nature of the health centre data [30].
In addition to analyses specified in the pre-agreed ana-
lytical plan, prevalence of malaria and anaemia in infants
using data from the 2004 and 2006 IPTi community
effectiveness household surveys was also calculated.
These surveys are described in detail elsewhere [20,22],
but were large, representative of households in the 24
divisions included in the IPTi cluster randomized con-
trolled trial, and the 2006 survey took place in July and
August, overlapping the time period of this study.
Results of these secondary analyses presented here are
restricted to the 11 divisions that were also included in
the IPTi Morbidity Monitoring study. Statistical testing
was based on cluster level t tests, and analyses were car-
ried out using svy commands in Stata, which are meth-
ods appropriate for the clustered design of the IPTi trial
and the sampling strategy of the household surveys [30].
Ethics
The study was undertaken within the framework of the
assessment of the community effectiveness of IPTi, part
of the IPTi Consortium. Ethical approval was granted by
the following local and national institutional review
boards: Ifakara Health Institute, National Tanzania Med-
ical Research Coordinating Committee, London School
of Hygiene & Tropical Medicine, and the Cantons of
Basel-Stadt and Basel-Land, Switzerland. The permission
to execute the project was sought and obtained from
the Tanzania Ministry of Health and Social Welfare and
the respective District Councils of the participating
districts.
Results
Characteristics of the Morbidity Monitoring study
population
A total of 9,880 children aged 2-11 months contributed
at least one day to time at risk between April 2006 and
March 2007. Half were from health centres in interven-
tion areas, although some health centres saw more chil-
dren than others (Table 1). Median registration date was
27th April 2006, and median age at entry into the analysis
(four months) was similar in intervention and compari-
son areas (Table 1). In total, therefore, 7,056 health cen-
tre visits were recorded in 4,227 children, with a median
of two all-cause health centre attendances per child in
both intervention and comparison areas (Table 1).
Uptake of EPI vaccinations and IPTi doses
During the study, uptake of routine EPI vaccinations
was 69% for DPT2 (children aged 2-11 months), 55%
for DPT3 (children aged 3-11 months), and 42% for
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measles (children aged 9-11 months). Similar propor-
tions of children from both areas received DPT2; while
more children from the intervention areas received
DPT3 and measles vaccines (Table 1). Median age at
DPT2, DPT3 and measles was 2 months 21 days,
4 months 0 days, and 9 months 18 days respectively, and
median age at these routine vaccinations was similar
between children in intervention and comparison areas
(Table 1). A total of 72% of children aged 2-11 months in
intervention areas received at least one dose of IPTi, and
22% received all three doses. Median age at IPTi1, IPTi2
and IPTi3 was 2 months 15 days, 4 months 0 days, and
9 months 18 days respectively (Table 1).
IPTi and malaria, anaemia, and all-cause OPD attendance
Point estimates suggest a protective effect of IPTi on
malaria, but an increase in the risk of anaemia, and no
difference in the incidence of all-cause outpatient atten-
dance. However, adjustment for the clustered nature of
the data means that none of these results reached statis-
tical significance (Tables 2, 3, and 4).
Malaria
In total during this 12 month period, 763 first or only
episodes and 836 multiple episodes of malaria were seen
(Table 2). Rates of malaria in IPTi intervention areas
appeared lower in ‘intention to treat’ analysis comparing
children attending health centres in IPTi intervention
and comparison areas, although differences did not
reach statistical significance (RR = 0.75, 95% CI 0.24-
2.31 first or only episode of malaria; RR = 0.82, 95% CI
0.29-2.29 multiple episodes). In ‘per protocol’ analyses,
comparing children from intervention areas who
received IPTi dose 1 with children from comparison
Table 2 Incidence of first or only and all episodes of malaria, and incidence in all time at risk after IPTi dose, and
within 28 days of IPTi dose one
Intervention Area Comparison Area Effect
Intention to treat* Events PYAR Rate Events PYAR Rate RR (95% CI) p value PE (95% CI)
Malaria incidence (first or only)
Crude 315 2048.3 0.154 448 1882.7 0.238 0.65 (0.56-
0.75)
< 0.001 35% (25%,44%)
adjusted‡ 0.75 (0.24-
2.31)
0.584 25%
(-131%,76%)
Malaria incidence (all episodes)
Crude 329 2105.9 0.156 507 1946.0 0.261 0.60 (0.52-
0.69)
< 0.001 40% (31%,48%)
adjusted† ‡ 0.82 (0.29-
2.29)
0.663 18%
(-129%,71%)
IPTi Intervention Area Corresponding EPI
vaccine Comparison
Area
Effect
Per protocol** Events PYAR Rate Events PYAR Rate RR (95% CI) p value PE (95% CI)
Malaria incidence (all episodes) in ATAR since IPTi
dose
IPTi dose 1
crude 79 623.2 0.127 125 513.1 0.244 0.52 (0.39-
0.69)
< 0.001 48% (31%,61%)
adjusted† ‡ 0.68 (0.21-
2.22)
0.498 32%
(-122%,79%)
Malaria incidence within 28 days of IPTi dose
IPTi dose 1
crude 7 95.1 0.070 13 81.0 0.160 0.46 (0.18-
1.15)
0.088 54% (-15%,82%)
adjusted‡ 0.48 (0.11-
2.13)
0.341 52%
(-113%,89%)
*Intention to treat analyses comparing IPTi intervention and comparison areas.
**Per protocol analyses comparing children who received IPTi in intervention areas to those that received corresponding EPI vaccines in comparison areas.
EPI = expanded programme on immunization, PAYR = person years at risk, ATAR = all time at risk, RR = rate ratio, CI = confidence interval, PE = protective
efficacy.
†Results adjusted for clustering within children for multiple episodes of malaria using Poisson random effects modeling.
‡Using intervention and comparison area mean rate, unpaired t test p value and approximate 95% CI that adjust for clustering by health centre.
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areas who received DPT2, 204 episodes of malaria were
seen in all time at risk after receiving IPTi dose 1, and
20 episodes were recorded within 28 days of IPTi dose
1. Rates of malaria in children who received IPTi 1
appeared lower, but differences were not statistically sig-
nificant (RR = 0.68, 95% CI 0.21-2.22 for episodes in all
time at risk after IPTi 1; RR = 0.48, 95% CI 0.11-2.13
for episodes with 28 days). Protective efficacy point esti-
mates in both ‘intention to treat’ and ‘per protocol’ ana-
lyses were consistently lower on adjustment for
clustering by health centre.
Anaemia
Table 3 shows that 2438 episodes of mild anaemia (Hb
< 11 g/dL), and 524 episodes of severe anaemia (Hb < 8
g/dL) were recorded during the 12 month study period.
Point estimates of protective efficacy in ‘intention to
treat’ analyses suggest rates in children attending health
centres in IPTi intervention areas were higher that those
attending centres in comparison areas, although differ-
ences were not statistically significant (RR = 1.13, 95%
CI 0.65-1.97 mild anaemia; RR = 1.59, 95% CI 0.54-4.68
severe anaemia). In ‘per protocol’ analyses 546 episodes
Table 3 Incidence of first or only episode of mild and severe anaemia, and incidence of anaemia in all time at risk,
and within 28 days of IPTi dose one
Intervention Area Comparison Area Effect
Intention to treat* Events PYAR Rate Events PYAR Rate RR (95% CI) p value PE (95% CI)
Mild anaemia incidence (first or only)
Crude 1268 1771.8 0.716 1170 1689.7 0.694 1.03 (0.95-1.12) 0.424 -3% (-12%,5%)
adjusted‡ 1.13 (0.65-1.97) 0.597 -13% (-97%,35%)
Severe anaemia incidence (first or only)
crude 318 2046.8 0.155 206 1944.1 0.106 1.47 (1.23-1.75) < 0.001 -47% (-75%,-23%)
adjusted‡ 1.59 (0.54-4.68) 0.360 -59% (-368%,46%)
IPTi Intervention Area Corresponding EPI
vaccine Comparison
Area
Effect
Per protocol** Events PYAR Rate Events PYAR Rate RR (95% CI) p value PE (95% CI)
Mild anaemia incidence (first or only) in ATAR
since IPTi dose
IPTi dose 1
crude 289 543.8 0.531 257 455.6 0.564 0.93 (0.78-1.10) 0.383 7% (-10%,22%)
adjusted‡ 1.04 (0.58-1.87) 0.878 -4% (-87%,42%)
Severe anaemia incidence (first or only) in ATAR
since IPTi dose
IPTi dose 1
crude 65 615.2 0.106 26 518.3 0.050 2.10 (1.34-3.32) 0.001 -110% (-232%,-
34%)
adjusted‡ 2.12 (0.41-11.03) 0.277 -112%
(-1000%,59%)
Mild anaemia incidence (first or only) within 28
days of IPTi dose
IPTi dose 1
crude 45 93.8 0.480 31 80.5 0.385 1.25 (0.79-1.97) 0.343 -25% (-97%,21%)
adjusted‡ 1.30 (0.42-4.07) 0.579 -30% (-307%,58%)
Severe anaemia incidence (first or only) within 28
days of IPTi dose
IPTi dose 1
crude 4 95.1 0.042 2 81.4 0.025 1.71 (0.31-9.35) 0.530 -71% (-835%,69%)
adjusted‡ 1.57 (0.11-22.93) 0.700 -57% (-2190%,89%)
*Intention to treat analyses comparing IPTi intervention and comparison areas.
**Per protocol analyses comparing children who received IPTi in intervention areas to those that received corresponding EPI vaccines in comparison areas.
EPI = expanded programme on immunization, PAYR = person years at risk, ATAR = all time at risk, RR = rate ratio,
CI = confidence interval, PE = protective efficacy,
Hb = haemoglobin.
‡Using intervention and comparison area mean rate, unpaired t test p value and approximate 95% CI that adjust for clustering by health centre.
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of mild anaemia were seen in all time at risk (ATAR)
since IPTi dose 1, and 76 episodes were recorded within
28 days. Rates of severe anaemia were much lower, with
91 in all time at risk after IPTi dose 1, and only six
cases of severe anaemia within 28 days of IPTi dose 1.
Rates of mild and severe anaemia from ‘per protocol’
analyses were also higher in children who had received
IPTi dose 1, in comparison to those who had received
DPT2, but results were not statistically significant (mild
anaemia: RR = 1.04, 95% CI 0.58-1.87 ATAR and RR =
1.30, 95% CI 0.42-4.07 within 28 days; severe anaemia:
RR = 2.12, 95% CI 0.41-11.03 ATAR, and RR = 1.57,
95% CI (0.11-22.93) within 28 days).
All-cause attendance at the health centre
Over the 12 months from April 2006 to March 2007,
4,227 first or only attendances, and 7,056 multiple atten-
dances at the health centre were seen (Table 4). Rates of
attendance in children visiting health centres in IPTi
intervention areas were similar to those in children
attending centres in comparison areas. In ‘per protocol’
analyses 2191 attendances were recorded in all time at
risk after IPTi dose 1, and 231 attendances were recorded
within 28 days of IPTi 1. Rates of all-cause health centre
attendance were similar in children from IPTi interven-
tion areas who received IPTi dose 1 than in those from
comparison areas who had received DPT2.
Malaria and anaemia prevalence in the 2004 and 2006
IPTi household surveys, restricted to Morbidity
Monitoring divisions
When restricted to the 11 divisions included in the
Morbidity Monitoring study, information was available
from 257 and 319 children aged 2-11 months in the
2004 and 2006 household surveys respectively. Results
from the 2004 survey (prior to IPTi), suggest that the 11
divisions included in the IPTi Morbidity Monitoring
study were comparable on variables for which informa-
tion was available (Table 5). Changes between 2004 and
2006 in the prevalence of parasitaemia, severe anaemia
and net use by children in the night before the survey
(Figure 2, Table 5), show a marked decrease in malaria
Table 4 Incidence of first or only and all OPD attendances, and incidence of attendance in all time at risk, and within
28 days of IPTi dose one
Intervention Area Comparison Area Effect
Intention to treat* Events PYAR Rate Events PYAR Rate RR (95% CI) p
value
PE (95% CI)
Health centre attendance (first or only)
crude 2160 1535.3 1.407 2067 1434.4 1.441 0.97 (0.92-1.04) 0.417 3% (-4%,8%)
adjusted‡ 1.04 (0.75-1.45) 0.795 -4% (-45%,25%)
Health centre attendances (all episodes)
crude 3631 1810.5 2.005 3425 1699.3 2.015 0.99 (0.95-1.04) 0.834 1% (-4%,5%)
adjusted† ‡ 1.05 (0.75-1.48) 0.736 -5% (-48%,25%)
IPTi Intervention Area Corresponding EPI
vaccine Comparison
Area
Effect
Per protocol** Events PYAR Rate Events PYAR Rate RR (95% CI) p
value
PE (95% CI)
Health centre attendances (all episodes) in ATAR since
IPTi dose
IPTi dose 1
crude 1109 565.2 1.960 1082 466.6 2.317 0.84 (0.78-0.92) 0.001 16% (8%,22%)
adjusted† ‡ 0.98 (0.69-1.38) 0.907 2% (-38%,31%)
Health centre attendance (all episodes) within 28 days
of IPTi dose
IPTi dose 1
crude 106 93.7 1.131 125 80.3 1.556 0.73 (0.56-0.94) 0.016 27% (6%,44%)
adjusted† ‡ 0.82 (0.48-1.40) 0.421 18%
(-40%,52%)
*Intention to treat analyses comparing IPTi intervention and comparison areas.
**Per protocol analyses comparing children who received IPTi in intervention areas to those that received corresponding EPI vaccines in comparison areas.
EPI = expanded programme on immunization, PAYR = person years at risk, ATAR = all time at risk, RR = rate ratio, CI = confidence interval, PE = protective
efficacy.
†Results adjusted for clustering within children for multiple episodes of all-cause health centre attendance using Poisson random effects modeling.
‡Using intervention and comparison area mean rate, unpaired t test p value and approximate 95% CI that adjust for clustering by health centre.
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parasitaemia, and an increase in mean haemoglobin and
bed net usage in both IPTi intervention and comparison
areas. In 2006, in Morbidity Monitoring areas, differences
between intervention and comparison areas did not reach
statistical significance, but prevalence of parasitaemia was
nine percentage points lower in intervention areas, while
mean haemoglobin was 0.3 g/dL higher in intervention
areas, and prevalence of reported bed net use by children
in the night before the survey was 14 percentage points
higher in comparison areas (Table 5).
Discussion
Effectiveness of IPTi with SP
In all, 72% of children aged 2-11 months attending
health centres in intervention areas received at least one
dose of IPTi, and 22% received all three doses. Median
age at IPTi dose was older than recommended by EPI
guidelines, but similar to median ages at routine
Table 5 Prevalence of parasitaemia, net use and mean
haemoglobin levels in children aged 2-11 months, using
data from the 2004 and 2006 IPTi Household Surveys,
restricted to Morbidity Monitoring divisions (n = 11)
2004 IPTi household survey Intervention Comparison p value *
Parasitaemia [n/N (%)] 98/156 (63) 60/101 (59) 0.677
Haemoglobin (g/dL) [mean
(95% CI)]
8.5 (8.3-8.8) 8.8 (8.5-9.1) 0.955
Net use (last night) [n/N (%)] 45/156 (29) 27/101 (27) 0.739
2006 IPTi household survey Intervention Comparison p value *
Parasitaemia [n/N (%)] 62/188 (33) 47/111 (42) 0.130
Haemoglobin (g/dL) [mean
(95% CI)]
9.6 (9.3-9.9) 9.3 (8.9-9.6) 0.640
Net use (last night) [n/N (%)] 102/195 (52) 77/116 (66) 0.519
Results obtained using svy commands in Stata, which adjust for the sampling
strategy of the survey.
Hb = haemoglobin, CI = confidence interval.
*Using unpaired t test that adjusts for the IPTi trial study design (randomized
by division).
B D 
A C 
Figure 2 Prevalence of parasitaemia and severe anaemia (Hb < 8 g/dL) with 95% confidence intervals, by age in months, in children
aged 2-11 months in Morbidity Monitoring divisions (n = 11). Data from 2004 and 2006 IPTi Household Surveys. (A) Prevalence of
parasite positive children (2004 Household Survey), n = 257. (B) Prevalence of severely anaemic children (2004 Household Survey), n = 257. (C)
Prevalence of parasite positive children (2006 Household Survey), n = 299. (D) Prevalence of severely anaemic children (2006 Household Survey),
n = 299. Hb = haemoglobin.
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vaccinations, and similar to those seen during the 2006
IPTi representative household survey [22]. Results sug-
gest that more children from intervention areas received
DPT2 and measles vaccine, however, results from the
representative 2006 IPTi household survey, carried out
during a time period that overlapped this study, show
no indication of increased levels of EPI coverage in IPTi
intervention areas-coverage of DPT vaccination was
identical in both areas at 74% of children aged 6-11
months [22].
Overall incidence rates of 0.2 episodes of lab-confirmed
malaria; 0.7 episodes of mild and 0.13 of severe anaemia;
and 2 episodes of all-cause health centre attendance per
child per year were seen. These analyses of routine health
information data suggest that IPTi was associated with
an increased risk of anaemia, a reduced risk of malaria,
an increase in coverage of routine vaccinations, and no
effect on all cause out-patient attendance. However, none
of the effects of IPTi on malaria, anaemia or all-cause
health centre attendance, in either ‘intention to treat’ or
‘per protocol’ analyses, reached statistical significance
when adjusted for clustering by health centre. The confi-
dence intervals for the rate ratios of the effect of IPTi
with SP on these outcomes included the null value of
one, and ranged from rate ratios that are compatible with
a protective effect of IPTi, to rate ratios that suggest
increased rates of these outcomes in the IPTi group.
These results could represent (i) that IPTi with SP has no
impact on malaria, anaemia or all-cause attendance at
the health centre in children aged 2-11 months in this
setting, (ii) there was insufficient statistical power to
detect an effect of IPTi with SP, and linked to this, (iii)
that the background rates of malaria and malaria-related
anaemia were too low, due possibly to other control mea-
sures including net use, to detect an impact of IPTi with
the existing study design.
Studies, including a pooled analysis of six large RCTs
of IPTi using SP [5], have reported an IPTi-related
reduction in malaria and health centre attendance in
infants. Increased rates of anaemia have been reported
in two IPTi trials [9,11], however, the majority of RCTs
of IPTi have reported a decline [7,8,12], or no effect
[10], with results of the pooled analysis showing a 22%
decline in severe anaemia (Hb < 8 g/dL) [5]. Results
from the 2006 IPTi household survey carried out in July
and August, and including all 24 divisions, indicated
that prevalence of mild anaemia (Hb < 11 g/dL) was 8%
lower (p = 0.02) in children from IPTi intervention
areas, while in children who had received IPTi, mean
haemoglobin was 0.27 grams higher (p = 0.05) than in
children who had received the corresponding EPI vac-
cine [22]. Given findings from the wider literature, it is
suggested that the discrepancy in the results seen in this
study, and those from the IPTi household survey carried
out during an overlapping time period in the same
geographical area, is more likely due to the non-repre-
sentative nature of infants attending health facilities in
comparison to the whole population of infants, rather
than to a true increased risk in anaemia associated with
IPTi using SP.
All health centres with functional microscopes in our
project area were included in this evaluation (n = 11).
However, this provided only 32% power to detect a 30%
difference between IPTi intervention and comparison
areas. An additional 19 centres (30 in total) would be
required to achieve 80% power [30], although this would
not have been feasible, as in reality all eligible centres in
participating divisions were included.
In the 11 divisions included in the Morbidity Monitor-
ing study, there was a 17% fall in malaria parasitaemia
between 2004 and 2006 in children aged 2-11 months of
age living in IPTi comparison areas, as measured by the
representative household surveys. Using the same source
data, it was shown that in children of this age group in
IPTi comparison areas there was also a 0.5 g/dL
increase in mean haemoglobin, and a 39% increase in
the reported use of nets by children on the night before
the survey. These background changes may also have
contributed to the current study lacking sufficient power
to detect an effect of IPTi with SP. Longer periods of
observation may enable the discernment of trends, and
a difference between these trends in intervention and
comparison areas. These observations also draw atten-
tion to the need to monitor contextual factors which
may impact on the evaluation.
The use of routine HMIS data to monitor and evaluate
malaria control programmes
This study used HMIS data to evaluate the effectiveness
of IPTi with SP on health centre attendees. Findings
may, therefore, not be representative of children, and
their morbidity burden, in the wider community [31].
The quality of data in HMIS remains a critical issue.
Monthly supervision visits to all study sites were carried
out by the study co-coordinator (WM), data manager
(KS), and laboratory assistant. Visits were an opportu-
nity to discuss issues of data completeness and quality
with health centre staff. The basis for these discussions
was an automatically-, PDA-generated monthly report.
These compared numbers of OPD attendances and EPI
vaccinations to those recorded during the previous
month; highlighted whether all OPD attendances had
corresponding laboratory records; and listed the top ten
diagnoses made at the centre in the past month, which
previously had been prepared manually. Use of PDAs
enhanced data capture, ease of retrieval and summaris-
ing of the information. However, despite monthly super-
vision, issues of data completeness across HMIS
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registers, and the quality of microscopy from the on-site
health centre laboratories remained.
For example, on average 41% of blood slide results
from the health centre laboratory were missing a corre-
sponding record in the OPD register, and this showed
variability between the different health centres. This
study used blood slide results from the Morbidity Moni-
toring quality assurance laboratory, along with clinical
diagnosis from HMIS, to classify malaria outcome.
Health centre microscopy results had an average sensi-
tivity of 89.6% and specificity of 77.3%, using the QA
lab as gold standard. This again showed variation
between health centres. There was no suggestion that
data completeness or quality of microscopy was consis-
tently better or worse in IPTi intervention or compari-
son areas.
The use of HMIS data for monitoring and evaluation
should undergo quality control checks, be analysed with
due regard to potential selection biases (e.g. the type of
patient attending different health facilities), clustering of
the data, and statistical power considerations. The data
need to be interpreted bearing in mind the contextual
situation and consistency of results. Where unexpected
findings are documented, well-designed, well-implemen-
ted, representative household surveys may be needed to
answer the question of intervention effectiveness at the
community level, also capturing data from those popula-
tions who do not attend routine health services.
Conclusions
This study used routine data from Health Management
Information Systems in 11 sentinel health centres in
rural southern Tanzania to evaluate the effectiveness of
a new malaria control strategy, IPTi with SP. The pro-
cess highlights the challenges of using routine health
centre data to monitor and evaluate the effectiveness of
a malaria control programme in health centre attendees.
Findings suggest that unexpected results should be
investigated by drawing representative samples of the
target population to enable robust conclusions to be
drawn.
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